Tonix Pharmaceuticals Holding Corp. discloses preliminary operating results and financial condition for the year ended December 31, 2022, including $120.2 million in cash and cash equivalents, net cash used in operating activities of $98.1 million, and equity proceeds from the sale of common stock of $94.5 million.